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Insulin-like growth factor II acts 
through an endogenous growth pathway 
regulated by imprinting 
m early mouse embryos 
Daniel A. Rappolee, l Karin S. Sturm, 20 le  Behrendtsen, Gilbert A. Schultz, 3 Roger A. Pedersen, 
and Zena Werb 4 
Laboratory of Radiobiology and Environmental Health, Department ofAnatomy, and Program in Developmental Biology, 
University of California, San Francisco, California 94143-0750 USA 
We present evidence that insulin-like growth factor II (IGF-II) mediates growth in early mouse embryos and 
forms a pathway in which imprinted genes influence development during preimplantation stages, mRNA and 
protein for IGF-II were expressed in preimplantation mouse embryos, but the related factors IGF-I and insulin 
were not. IGF-I and insulin receptors and the IGF-II/mannose-6-phosphate receptor were expressed. 
Exogenous IGF-II or IGF-I increased the cell number in cultured blastocysts, but a mutant form of IGF-II that 
strongly binds only the IGF-II receptor did not. Reduction of IGF-II expression by antisense IGF-II 
oligonucleotides decreased the rate of progression to the blastocyst stage and decreased the cell number in 
blastocysts. Preimplantation parthenogenetic mouse embryos expressed mRNA for the IGF-II receptor but not 
for either IGF-II ligand or the IGF-I receptor, indicating that the latter genes are not expressed when inherited 
maternally. These data imply that some growth factors and receptors, regulated by genomic imprinting, may 
control cell proliferation from the earliest stages of embryonic development. 
[Key Words: Insulin-like growth factor; PCR; antisense oligonucleotides; insulin receptor; blastocysts; zygotic 
transcription; receptor tyrosine kinase; genomic imprinting] 
Received August 2, 1991; revised version accepted April 9, 1992. 
The mammalian embryo can behave as a free-living en- 
tity from fertilization to implantation and is capable of 
growing in culture in the absence of any exogenous 
growth factors (Biggers et al. 1988). However, the rate of 
growth of cleavage-stage mouse embryos in culture is 
density-dependent, suggesting that diffusible growth fac- 
tors of embryonic origin may regulate this growth (Paria 
and Dey 1990). Early cleavage-stage mouse embryos can 
be combined or halved without effect on the size of ne- 
onates, demonstrating their extensive capacity for regu- 
lation (Kelly 1977; for review, see Pedersen 1986) and 
implying a process of embryonic growth regulation 
(Buehr and McLaren 1974; Lewis and Rossant 1982). 
During preimplantation stages the mouse embryo under- 
goes cleavage and differentiates into a blastocyst hat 
possesses the precursors for the embryo proper (the inner 
cell mass) and the placenta (the trophectoderm). Com- 
Present addresses: ~Departments of Obstetrics and Gynecology, and Cell, 
Molecular and Structural Biology, Northwestern University, Chicago, 
Illinois 60611 USA; 2Children's Medical Research Foundation, Royal 
Alexandra Hospital for Children, Camperdown, New South Wales 2050, 
Australia; SDepartment of Medical Biochemistry, University of Calgary, 
Calgary, Alberta, Canada T2N 4N1. 
4Corresponding author. 
paction, the epithelialization of the embryo at the eight- 
cell stage, is required for the determination of these pre- 
cursors (for review, see Cruz and Pedersen 1991) and is 
dependent on the transcription of the zygotic genome 
after its activation at the two-cell stage (Flach et al. 1982; 
Pik6 and Clegg 1982). We have shown previously that 
cleavage-stage mouse embryos transcribe and translate 
mRNA for transforming growth factor (TGF)-a, TGF-[31, 
and platelet-derived growth factor-A chain, but not for 
nerve growth factor, basic fibroblast growth factor, epi- 
dermal growth factor, or granulocyte colony-stimulating 
factor (Rappolee t al. 1988a; for review, see Rappolee t 
al. 1990). Interleukin-6 and leukemia inhibitory factor/ 
differentiation-inhibiting activity are also expressed at 
the blastocyst stage (Conquet and Brulet 1990; Murray et 
al. 1990). However, no complete circuit of endogenous 
growth factor ligand and receptor has been elucidated in 
preimplantation mammalian embryos. 
Insulin and its relatives constitute a family of growth 
factors that might be implicated in growth regulation of 
early embryos. Early mouse embryos bind insulin, which 
affects their rate of protein synthesis in culture (Harvey 
and Kaye 1988; Mattson et al. 1988). The insulin family 
includes insulin-like growth factor (IGF)-I, IGF-II, and 
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insulin (two nonallelic genes)(Sara and Hall 1990). These 
factors are related by sequence and have insulin-like 
metabolic effects. In adult animals, insulin expression is
regulated by glucose, and IGF-I expression is regulated by 
growth hormone, but the regulation of IGF-II is not well 
understood (Sara and Hall 1990). 
There are three known insulin-like growth factor re- 
ceptors. The IGF-II/mannose-6-phosphate receptor (also 
called the type-2 receptor, but referred to in this report as 
the IGF-II receptor) binds IGF-II strongly, binds IGF-I 
weakly, but does not bind insulin at all (Roth 1988; 
Czech 1989). It also binds glycoproteins containing man- 
nose-6-phosphate moieties, but these proteins do not ac- 
tivate the G protein-mediated signaling induced by the 
binding of IGF-II (Okamoto et al. 1990a, b). The IGF-I 
receptor (also called the type-1 receptor or IGF-I/IGF-II 
receptor) and insulin receptors are related tyrosine ki- 
nases activated by ligand binding. The IGF-I receptor is 
activated equally by IGF-II and IGF-I, but the insulin 
receptor is activated more strongly by insulin than by 
IGF-I (Roth 1988; Sakano et al. 1991). Purified insulin 
receptor isolated from placenta binds IGF-II nearly as 
well as insulin, but the mitogenic apacity of IGF-II for 
the insulin receptor is not known (Sakano et al. 1991). 
Mitogenic responses to IGF-II are mediated by the IGF-I 
receptor not by the IGF-II receptor (Kiess et al. 1987; 
Osborne et al. 1989; for review, see Czech 1989). 
Postimplantation rodent embryos possess the IGF-II 
receptor (Smith et al. 1987; Senior et al. 1990) and the 
IGF-I receptor in greater quantities than the insulin re- 
ceptor ISmith et al. 1987), but the relative roles of the 
IGFs and their receptors in early development are still 
unclear. IGF-II has been implicated in postimplantation 
mouse growth (DeChiara et al. 1990, 1991), but IGF-II 
transcripts have not been detected in mouse (Lee et al. 
1990) or human (Brice et al. 1989; Ohlsson et al. 1989b) 
preimplantation embryos. IGF-II expression has been as- 
sociated most closely with mesoderm (Heath and Shi 
1986; Stylianopoulou et al. 1986, 1988; Beck et al. 1987; 
Han et al. 1987b), which arises at gastrulation. 
Regulation of growth in early mammalian embryos 
might be modulated by genomic imprinting, the selec- 
tive differential expression of genes initiated by a process 
of unknown mechanism during gametogenesis. IGF-II 
ligand is imprinted when inherited maternally, and IGF- 
II receptor is imprinted when inherited paternally (De- 
Chiara et al. 1990; Barlow et al. 1991). 
In this study, we analyzed preimplantation zygotic 
mouse embryos for the expression and function of three 
ligands and receptors in the IGF family and examined 
parthenogenetic embryos for evidence of genomic im- 
printing at preimplantation stages. 
Results 
Preimplantation zygotic mouse embryos express IGF-II 
We used the sensitive reverse transcription-polymerase 
chain reaction (RT-PCR) technique, which can detect as 
few as 10-100 mRNA transcripts in a single cell IRap- 
polee et al. 1988a, b, 1989), to determine whether em- 
bryos express transcripts for the insulin family members. 
IGF-II transcripts were detected first at the two-cell stage 
in samples of 10 embryos containing a total of 3 ng of 
RNA (Pik6 and Clegg 1982) and then increasingly 
through the blastocyst stage in samples containing up to 
15 ng of total RNA (Fig. la, b). Insulin and IGF-I tran- 
scripts were not found before implantation (Fig. l c, e). In 
contrast, an IGF-I signal was detected in 20 pg of mac- 
rophage mRNA (Fig. ld), and an insulin signal was de- 
tected in 20 pg of pancreas mRNA (Fig. lf). RT-PCR 
products were validated by restriction enzyme mapping, 
sequence analysis, and Southern blot analysis (data not 
shown). IGF-II transcripts were expressed at the late two- 
cell stage when the zygotic genome is first transcribed 
and after much of the maternal contribution of tran- 
scripts has been degraded (Pik6 and Clegg 1982; Schultz 
1986). 
The IGF-II gene gives rise to two mRNAs; the one 
expressed more ubiquitously does not code for a protein 
in reticulocyte lysate systems (Frunzio et al. 1986; Gra- 
ham et al. 1986). Because the presence of growth factor 
mRNA cannot be equated with translation of the RNA 
to protein (Dinarello 1989), we analyzed blastocysts for 
the presence of IGF-II polypeptide immunologically. 
There was insufficient protein to detect metabolically 
labeled growth factors from mouse blastocysts by immu- 
noprecipitation or immunoblotting {data not shown). 
However, polypeptides reacting with a polyclonal anti- 
body to rat IGF-II were seen in all cells of the blastocyst 
by immunocytochemistry {Fig. 2). All staining was at- 
tenuated by preabsorbing the antibody with purified rat 
IGF-II. Nevertheless, these data do not necessarily indi- 
cate that all cells within the blastocyst are sites of IGF-II 
synthesis. It is possible that some cells produce IGF-II 
and that others take it up by endocytosis, because all 
cells of the blastocyst apparently produce IGF-II recep- 
tor, as judged by immunocytochemistry with anti-recep- 
tor antibodies (data not shown). We conclude that pre- 
implantation mouse embryos begin to transcribe IGF-II 
soon after activation of zygotic transcription at the two- 
cell stage and accumulate immunoreactive polypeptide 
at the blastocyst stage (Schultz 1986). 
Preimplantation mouse embryos express receptors 
for IGF-H 
Unfertilized eggs and zygotic embryos at the two-cell, 
four-cell, eight-cell, and blastocyst stages were assayed 
by RT-PCR for insulin receptors, IGF-I receptors, and 
IGF-II receptors. Transcripts for the IGF-II receptor were 
detected at the two-cell stage (Fig. 3a). IGF-I and insulin 
receptors were not expressed until after compaction, at 
the eight-cell stage {although in one of five experiments 
there was a weak signal for IGF-I receptor at the two-cell 
stage) (Fig. 3c, e); all receptors were detected in ~<2 ng of 
control RNA {Fig. 3b, d, fJ. Taken together, these observa- 
tions suggested that among the insulin family of growth 
factors, only IGF-II could potentially function as an en- 
dogenous ligand in preimplantation mouse embryos and 
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Figure 1. Expression pattern of mRNA transcripts for IGFs in preimplantation mouse embryos. Preimplantation mouse embryos were 
obtained in groups of 100-200 from superovulated females 24 hr after injection of human chorionic gonadotropin [(UE) unfertilized 
one-cell, 36 hr p.c.; (2) two-cell, 60 hr p.c.; (8) eight-cell, 96 hr p.c.; (B) blastocyst, and (8.5 day) at 8.5 d.g.]. Whole-cell RNA was purified 
and reverse transcribed, an  cDNA from -10 embryos (-3.5 ng/10 unfertilized eggs, 2.4 ng/10 two-cell, 6.9 ng/10 eight-cell, 14.2 
ng/10 blastocysts; Pik6 and Clegg 1982) was amplified for 60 cycles of PCR and electrophoresed in agarose. Positive controls were 200 
ng of whole-cell RNA from nullipotent embryonal carcinoma stem cells (Nulli) or 8.5-d.g. embryos. (a)IGF-II transcripts (266 bp); (b) 
10-fold ilution series of mRNA from differentiated F9 cells; (c) IGF-I transcripts (210 bp); (d) dilution series of mRNA from endotoxin- 
stimulated macrophages; (e) insulin transcripts (299 bp); {f) dilution series of mRNA from pancreas. Arrows indicate the location of the 
PCR product. Data are shown as negative images of ethidium bromide-stained gels. In b, d, and f, amounts ranging from 20 pg through 
2000 ng of whole RNA was reverse transcribed and 2 pg through 200 ng (one-tenth of reverse transcription) was analyzed by PCR. 
that it could act through the IGF-I receptor, the IGF-II 
receptor, or the insulin receptor. 
Receptors for IGF-II function in preimplantation 
mouse embryos 
It has been shown previously that insulin binds and 
stimulates mouse embryos soon after compaction 
(Harvey and Kaye 1988; Mattson et al. 1988) and that 
inner cell mass cells from mouse blastocyst outgrowths 
bind IGF-I, IGF-II, and insulin (Mattson et al. 1988). This 
indicates that one or more members of the insulin family 
of receptors must be functional during preimplantation 
mouse embryo development. We first determined the ef- 
fect of adding recombinant human IGF-II to mouse em- 
bryos during culture from two-cell stage to blastocyst. 
Examination of sequential photographs of embryos cul- 
tured with IGF-II or insulin revealed no obvious morpho- 
logical effects or modulation of the rate of progression 
through the cleavage stages to compaction; however, the 
time of cavitation was accelerated ( ata not shown). Dur- 
ing the last 4 hr of culture, [3SS]methionine was added 
and the blastocysts were assayed for incorporation of ra- 
diolabeled methionine into protein by precipitation with 
trichloroacetic acid (TCA). IGF-II increased methionine 
incorporation significantly (P < 0.05, Student's t-test) by 
1.8- and 3.5-fold in two experiments (Fig. 4); IGF-I stim- 
ulated methionine incorporation to a lesser extent. In 
agreement with the results of Harvey and Kaye (1988), 
we also found that insulin increased the specific activity 
of radiolabeled proteins ignificantly (P < 0.05, Student's 
t-test) by 2- to 2.5-fold in two experiments (Fig. 4). How- 
ever, the patterns of [3SS]methionine-labeled proteins 
from untreated and IGF-II-treated embryos were qualita- 
tively indistinguishable by one-dimensional SDS-poly- 
acrylamide gel electrophoresis (data not shown). These 
observations show that IGF-II has a significant effect on 
preimplantation embryonic growth. 
At the growth factor concentrations u ed in these first 
tests of function for embryonic receptors, it was not pos- 
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Figure 2. Expression of IGF-II polypep- 
tide in mouse blastocysts. Cultured mouse 
blastocysts were centrifuged onto cover- 
slips and prepared for indirect immunoflu- 
orescence by using polyclonal antibody to 
rat IGF-II before (a,b) and after {c,d) absorp- 
tion of the antibody with a 1000-fold ex- 
cess of rat IGF-II. (a,c) Phase micrographs; 
(b,d) fluorescence micrographs. 
sible to determine whether the IGF-II receptor the IGF-I 
receptor, or the insulin receptor was mediating the ef- 
fects of IGF-II on protein accumulation. Because no 
changes were seen in the rate of progress through early 
cleavage or compaction after IGF-II exposure, the IGF-II 
receptor is either not functional in the early cleavage 
stages or is not sufficient o regulate vents in early de- 
velopment. We compared the effects of IGF-II, IGF-I, and 
[Leu27]IGF-II, a mutant form of IGF-II that binds strongly 
to the IGF-II receptor (Beukers et al. 1991), on the growth 
of preimplantation mouse embryos. Mouse embryos cul- 
tured from the two-cell to the blastocyst stage had in- 
creased numbers of cells after exposure to IGF-I or IGF-II 
but not after exposure to [Leu27]IGF-II (Fig. 5). Cell num- 
ber increased significantly (1.2- to 1.4-fold in two exper- 
iments; P < 0.05, Student's t-test) at concentrations of
IGF-I and IGP-II that were near the K d of the IGF-I recep- 
tor (Roth 1988; Czech 1989), but 10-fold higher concen- 
trations of [Leu~7]IGF-II had no effect. Because these 
growth factors appeared to act only after compaction, 
these increases in cell number occurred in one to two 
cell divisions in the presence of a number of other en- 
dogenous growth factors (Rappolee t al. 1990) and thus 
are highly significant. These data suggest that IGF-II in- 
duces growth in preimplantation mouse embryos 
through the IGF-I receptor or the insulin receptor and 
not through the IGF-II receptor, which binds only to IGF- 
II or [Leu27]IGF-II. 
Reduction in IGF-II expression by antisense 
oligonucleotides slows embryonic growth 
We then analyzed whether the endogenous embryonic 
IGF-II functions in embryonic growth. Antisense oligo- 
nucleotides have been used to reduce the expression and 
function of intracellularly expressed genes uch as c-myc 
(Holt et al. 1988) and growth factors (Becker et al. 1989), 
and thus they provide a proven method for decreasing 
gene expression in preimplantation mouse embryos 
(Bevilacqua et al. 1988). We used sequence-specific oli- 
gonucleotides for IGF-II that were complementary for 
the coding region of the first 6 amino acids (Marcus- 
Sekura 1988; Stein and Cohen 1988). The preimplanta- 
tion embryos tolerated the oligonucleotides well, and 
toxicity with control sense or random oligonucleotides 
was seen only above 100--200 I~M; with control oligonu- 
cleotides below 100 ~M, the embryos grew at least as 
well as untreated embryos. However, a concentration- 
dependent effect of antisense oligonucleotides was seen 
between 1 and 100 ~M, with a peak of sensitivity at 30 
~M. At this concentration, -106 molecules of the sense 
or antisense IGF-II oligonucleotides were present at 
steady state in the blastocyst, as detected by autoradiog- 
raphy and liquid scintillation spectrometry (data not 
shown). 
Culture of mouse embryos from the two-cell to the 
blastocyst stage with antisense IGF-II oligonucleotides 
in two separate xperiments resulted in the loss of im- 
munochemically demonstrable IGF-II antigen compared 
with embryos incubated with sense oligonucleotides, 
with an estimated average decrease in immunofluores- 
cence of at least 75% (Fig. 6a-d). In contrast, the average 
amount of actin seen with rhodamine-phalloidin in two 
experiments was the same in embryos treated with ei- 
ther sense or antisense oligonucleotides (Fig. 6e, f). With 
normal rabbit serum, no antigens were detected (Fig. 
6g, h). The amount of IGI:-II mRNA demonstrable by 
quantitative RT-PCR analysis was reduced by antisense 
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Figure 3. Expression pattern of mRNA 
transcripts for IGF receptors in preimplan- 
tation mouse embryos. Transcripts for 
IGF-II receptor (186 bp) (a,b), IGF-I recep- 
tor (345 bp)(c,d), and insulin receptor (319 
bp) {eft} were assayed as described in the 
legend to Fig. 1. Dilution series for posi- 
tive controls were obtained from differen- 
tiated F9 cells (b,d) and endotoxin-stimu- 
lated macrophages {f). As in Fig. 1, whole 
RNA from 10 embryos at each stage was 
examined; abbreviations are also the 
same. Data are shown as negative images 
of ethidium bromide-stained gels. 
IGF-II oligonucleotides, whereas the amount of glyceral- 
dehyde-3-phosphate d hydrogenase (GAPDH)mRNA 
was unaffected {Fig. 7a). The effects of antisense IGF-II 
oligonucleotides seemed specific: A delay in the onset of 
blastocyst formation, assayed by appearance of cavita- 
tion, was also seen with a second pair of sense and an- 
tisense oligonucleotides specific for IGF-II {Fig. 7b). The 
proportion of embryos reaching the blastocyst stage after 
48 and 72 hr also decreased significantly (P < 0.05, Stu- 
dent's t-test) with the second antisense oligonucleotide 
but was not affected by the second sense oligonucleotide. 
Preimplantation mouse embryos cultured with an- 
tisense oligonucleotides from the two-cell to the blasto- 
cyst stage grew significantly more slowly (P < 0.05, Stu- 
500 
~_~ 20( 
~ 10( :S u 
65 
In 
o 
Medium IGF-I 
Alone 
IGF-II Insulin Medium IGF-II 
Alone 
Experiment 1 Experiment 2 
Insulin 
Figure 4. Stimulation of protein synthesis 
by IGF-II in preimplantation mouse embryos. 
Mouse embryos were cultured from the two- 
cell stage for 48 hr to the blastocyst tage with 
100 nM IGF-II, IGF-I, or insulin. During the 
last 4 hr of culture, blastocysts were incu- 
bated with 1 mCi/ml of [3SS]methionine 
(3000 Ci/mmole). Incorporation i to proteins 
was measured by liquid scintillation spec- 
trometry after acid precipitation. Protein syn- 
thesis was enhanced significantly after insu- 
lin, IGF-II, and IGF-I, compared with medium 
alone (Student's t-test; P < 0.05). Three inde- 
pendent experiments were performed, with 
60 blastocysts in each experiment. Results of 
two experiments are shown. The incorpora- 
tion of [3SS]methionine into untreated em- 
bryos was 826 and 1250 cpm in the two ex- 
periments. The Bachem preparation of IGF-I 
was used in these experiments. Bars, 
mean -+ S.D. 
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Figure 5. Demonstration that IGF-I[ stimulates cell growth in 
preimplantation mouse embryos through the IGF-I receptor. 
Mouse embryos were cultured from the two-cell stage through 
the early blastocyst stage in medium alone or with 0.05-50 
ng/20 ~1 of IGF-I, IGF-II, or [Leu27]IGF-II, fixed onto coverslips 
with ethanol-acetic a id, and stained with Hoechst 33258, and 
nuclei were counted. Twenty embryos were counted from each 
group. The two highest concentrations of IGF-I and the three 
highest concentrations of IGF-II had significantly higher effects 
on growth than did medium controls {Student's t-test; 
P < 0.05). The Amgen preparation of IGF-I was used in these 
experiments. The decrease in cell number at the highest dilu- 
tions was probably the result of accumulation ofplasticizer con- 
taminants during the serial dilution of the proteins and masked 
the effects at low concentrations but still permitted observation 
at higher concentrations. The decreased cell number at the 
highest dilution was the result of accumulation of contami- 
nants during serial dilutions. 
dent's t-test) {Fig. 7b) and had an average of 20% fewer 
cells than those cultured with sense oligonucleotides 
(Fig. 7c). 
Cytotoxicity did not account for the decreased cell 
number and slowing of cavitation, because when the an- 
t{sense oligonucleotide-treated embryos were cultured 
an additional 24 hr beyond the 48- to 72-hr time point, 
the fraction reaching late blastocyst stage was indistin- 
guishable from that of sense oligonucleotide-treated em- 
bryos. Moreover, exogenous IGF-II reversed the defi- 
ciency in embryo growth t at resulted from the reduc- 
tion in endogenous IGF-II; the number of cells in mouse 
embryos cultured with ant{sense IGF-II oligonucleotides 
in the presence of recombinant IGF-II was significantly 
greater than that in embryos cultured with ant{sense 
IGF-II oligonucleotides alone (Fig. 7c). 
Imprinting disrupts the IGF-II growth circuit 
in parthenogenetic mouse embryos 
Imprinting of the IGF-II gene has been observed previ- 
ously by DeChiara et al. (1990). To determine whether 
imprinting is detectable in preimplantation embryos, we 
exploited the process of parthenogenesis to obtain em- 
bryos that have a diploid genome of only maternal ori- 
gin; this is produced by suppression of cytokinesis in 
activated oocytes. In contrast o zygotic embryos (Fig. 1 ), 
no IGF-II transcripts were apparent in preimplantation 
parthenogenotes (Fig. 8a), extending the observation by 
DeChiara et al. (1990) that the maternally inherited IGF- 
II gene is imprinted in later development. However, ac- 
tin gene transcripts were detected throughout preim- 
plantation development in both zygotic embryos and 
parthenogenotes (Fig. 8b). 
Peri-implantation parthenogenotes did not express the 
IGF-I receptor gene or expressed it only weakly (Fig. 8c). 
These data indicate that the IGF-I receptor, or a gene 
regulating it, may also be imprinted when inherited ma- 
ternally. 
The number of cells in parthenogenetic blastocysts 
treated with 50 nM IGF-II (95 -+ 10.8% control, for two 
experiments) for 48 hr was not significantly different 
from that in untreated parthenogenotes (P ~< 0.846; Stu- 
dent's t-test); the number of cells in zygotic blastocysts 
treated with IGF-II was 135 -+ 8.6% control (P ~< 0.005). 
This is in agreement with the hypothesis that IGF-II may 
act as a mitogen by the IGF-I receptor, but further exper- 
iments on the mitogenic effects of IGF-II through the 
insulin receptor and the imprinting status of the insulin 
receptor are required. 
Transcripts for the IGF-II receptor were expressed 
equally in zygotes and parthenogenotes (Fig. 8d), in keep- 
ing with previous observations that this gene is im- 
printed when inherited paternally (Barlow et al. 1991). 
These data suggest hat the endogenous growth factor 
IGF ' I  I 
AS AS 
Act in  
AS 
Cont ro l  
AS 
Figure 6. Effect of antisense IGF-II oligonucleotides on endog- 
enous IGF-II antigen in preimplantation mouse embryos. Pre- 
implantation mouse embryos cultured from the two-cell stage 
with sense (S} (a,b,e,g) or ant{sense (AS)(c,d,f,h} oligonucle- 
otides were fixed and subjected to indirect immunofluorescence 
with polyclonal anti-rat IGF-II (a,b,c,d) or nonimmune rabbit 
serum (NRSJ (g,h) or stained with rhodamine-phalloidin to de- 
tect actin (e,f). 
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Figure 7. Effect of antisense IGF-II oligonucleotides on 
IGF-II expression and function in preimplantation 
mouse embryos. (a) Fifty two-cell mouse embryos 
were incubated with 30 V~M sense or antisense IGF-II 
oligonucleotides for 48 hr~ their RNAs were then pu- 
rified and assayed for expression of IGF-II transcripts 
[left) or GAPDH transcripts (right} by RT-PCR in the 
presence of 32p-labeled oligonucleotide primers. (@) 
Embryos treated with sense oligonucleotides~ (ll) em- 
bryos treated with antisense oligonucleotides. {b) Pre- 
implantation mouse embryos were incubated with 30 
IXM sense or antisense IGF-II oligonucleotides for 48 
hr~ they were then photographed, and the percentage 
of cavitated blastocysts was determined. Initiation 
codon oligonucleotides were used in experiments 1 
and 2. In experiment 3, the oligonucleotides made for 
PCR were used. Both designs of antisense IGF-II oli- 
gonucleotides lowered the percentage of cavitated 
blastocysts significantly (Student's t-test~ P < 0.001 }. 
Ic) Preimplantation mouse embryos were incubated 
with 30 trM sense or antisense IGF-II oligonucleotides 
for 48 hr, with or without 10 nM recombinant IGF-II. 
Blastocysts were then fixed and stained with Hoechst 
33258, and the nuclei were counted. Exogenous IGF-II 
reversed the attenuated growth of blastocysts caused 
by antisense IGF-II oligonucleotides (P< 0.051. 
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circuit in early embryos that is dependent on IGF-II is 
disrupted by imprinting in parthenogenetic embryos. 
Discussion 
We have found that IGF-II transcript and polypeptide and 
transcripts for its receptors are expressed and form an 
endogenous circuit that is functional during normal pre- 
implantation mouse embryogenesis. It is probable that 
endogenous IGF-II mediates growth through the IGF-I 
receptor or the insulin receptor ather than the IGF-II 
receptor, because IGF-II and IGF-I, but not [Leu27]IGF-II, 
increased cell number in preimplantation mouse em- 
bryos in a concentration range suggesting activation of 
IGF-I receptor or insulin receptor. Although both IGF-II 
ligand and receptors for IGF-II are expressed before com- 
paction, reduction of endogenous IGF-II or addition of 
exogenous IGF-II had no apparent effect on morphology 
at the earliest stages, as judged by cell divisions mea- 
sured during precompaction cleavage or by the timing of 
compaction. All effects resulting from perturbing this 
pathway were on growth and metabolism easured after 
the morula stage. Incorporation of radiolabeled methio- 
nine and growth rate were affected significantly by treat- 
ments that increased or decreased the effects of IGF-II in 
cultured preimplantation embryos. Recent IGF-II gene- 
targeting experiments by DeChiara and co-workers 
{19901 demonstrated a 40% reduction in birth weight of 
IGY-II-mutant neonates, similar to the reduction in 
growth {measured by reduction in cells per blastocyst) 
that we observed in preimplantation embryos in the 
presence of antisense IGF-II oligonucleotides, but these 
workers did not study whether there was a decrease in 
the rate of early embryonic development ofembryos that 
were heterozygous orhomozygous for the mutation (De- 
Chiara et al. 1991). 
As we found that transcripts for IGF-I and insulin 
ligands are not expressed in cleavage-stage embryos, yet 
their receptors function {Harvey and Kaye 1989, 1991~ 
Gardner and Kaye 1991), we speculate that matemal 
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Zygote  Par thenogenote  
Figure 8. IGF-II and IGF receptor expres- 
sion in parthenogenetic embryos. Parthe- 
nogenetic embryos were generated by eth- 
anol activation, followed by suppression of 
second polar body emission by cytochala- 
sin D, and cultured to various stages be-
fore processing and assay of mRNA tran- 
scripts by RT-PCR. Normal zygotic em- 
bryos were generated and assayed for 
mRNA transcripts a described in Figs. 1 
and 3. The expression of mRNA tran- 
scripts for {a) IGF-II, (b) actin, (c) IGF-I re- 
ceptor, and (d) IGF-II receptor in unfertil- 
ized egg (UE), eight-cell (8), blastocyst 
stage-embryos (B),and 3- and 7-day blasto- 
cyst outgrowths (OG) is shown in zygotic 
(left) and parthenogenetic (r ght} embryos. 
eDNA reverse-transcribed from RNA from 
about five embryos was used for the PCR 
analysis in each lane. Data are shown as 
negative images of ethidium bromide- 
stained gels. 
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IGF-I and insulin form a maternal-embryonic pathway 
that also modulates cell growth of preimplantation 
mouse embryos. IGF-I is found in the uterine fluid of 
some mammals (Ko et al. 1991). This idea is supported 
by recent evidence that insulin increases cell number in 
the inner cell mass and that there are fewer cells in the 
inner cell mass of blastocysts from diabetic animals (Liu 
et al. 1989; Harvey and Kaye 1990; Pampfer et al. 1990), 
although direct evidence for in vivo effects is lacking. 
We showed previously that TGF-ot is transcribed and 
translated in cleavage-stage mouse embryos (Rappolee t 
al. 1988a), and we have also observed that antisense oli- 
gonucleotides specific for TGF-~ slow the growth of pre- 
implantation mouse embryos, whereas exogenous 
TGF-ot increases their protein synthetic rate (D.A. Rap- 
polee and Z. Werb, unpubl.). TGF-c~ did not regulate mor- 
phogenetic events such as compaction but, rather, al- 
tered the growth rate, as reported recently for growth 
factors acting through the epidermal growth factor re- 
ceptor (Paria and Dey 1990). These results suggest hat 
endogenous growth factors such as IGF-II and TGF-oL do 
not regulate differentiation events in preimplantation 
mouse embryos but regulate metabolic processes that 
may modulate cell proliferation rates. Limited increases 
in protein synthesis caused by addition of several growth 
factors (IGF-II, insulin, or TGF-cx) and limited decreases 
in cell growth rate caused by attenuating the expression 
of IGF-II or TGF-~ alone suggest that growth is regulated 
in preimplantation embryos through multiple, partially 
redundant, growth factor circuits. Further experiments 
are required to define this redundancy in vitro and in vivo. 
The use of a sensitive method such as RT-PCR raises 
a question about the biological relevance of low tran- 
script levels. Previous reports have shown that IGF-II 
mRNA is not expressed in mouse or human blastocysts 
assayed by in situ hybridization (Beck et al. 1987; Ohls- 
son et al. 1989b~ Lee t al. 1990}. We have found that 
IGF-II is expressed in mouse embryos when assayed by 
the RT-PCR technique, that the polypeptide is ex- 
pressed as assayed by immunofluorescence, and that 
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IGF-II expression has biological function. We have found 
previously that TGF-oL mRNA is expressed in mouse em- 
bryos at 7.5 days of gestation (d.g.) {Rappolee t al. 1988a) 
when equivalent-stage ratembryos were found to be neg- 
ative by in situ hybridization (Han et al. 1987a). It there- 
fore seems likely that RT-PCR can detect biologically 
significant levels of growth factor mRNA not detected 
by in situ hybridization. This should not be surprising, 
because a growth factor receptor with a K a of 10-13 is 
activated by a polypeptide concentration of about one 
molecule per fibroblast cell volume (assuming that a fi- 
broblast has a volume of -104 p.m 3) and growth factors 
normally act within a few cell diameters of their source 
(Deuel 1987). Other genes such as c-myc reach maxi- 
mum levels of five transcripts per cell during a response 
to optimal evels of platelet-derived growth factor (Deuel 
1987). Transcripts of developmentally important genes 
such as the limb deformity gene in the apical ectodermal 
ridge in mouse embryos (Zeller et al. 1989) are also not 
detected by in situ hybridization. Therefore, even very 
small numbers of mRNA transcripts might be biologi- 
cally significant if they are involved in gene regulation or 
participate in signaling cascades. 
When exogenous IGF-II ligand was added simulta- 
neously with IGF-II antisense oligonucleotides, the ef- 
fects caused by reduction of the endogenous IGF-II were 
reversed. Thus, the temporal or spatial distribution of 
endogenous IGF-II can be mimicked, in part, by exoge- 
nous IGF-II. It is likely that antisense IGF-II, which at- 
tenuates the expression of the endogenous IGF-II, slows 
embryonic growth through a specific mechanism. The 
coding sequence of the first 6 amino acid residues of 
IGF-II is not homologous with that of any other genes 
expressed in the preimplantation embryo, and two dif- 
ferent antisense IGF-II oligonucleotides produced similar 
effects, confirming that these effects are specific. 
Because IGF-II clearly did not account for all the cell 
proliferation in the early embryo, it is likely that other 
growth factors are involved. To assess whether various 
combinations of growth factors mediate any absolute f- 
fects on differentiation or growth, we must determine 
how they interact. Because at least 12 growth factor 
mRNAs are expressed uring preimplantation mouse 
embryogenesis (Rappolee t al. 1988a, 1990; Murray et 
al. 1990; unpubl.), this is not a simple task. New ap- 
proaches to eliminating rowth factors selectively must 
be perfected to resolve their roles. Although antisense 
oligonucleotides cause cytotoxicity in embryos at rela- 
tively low concentrations (100-200 ~M), several could be 
used at the 30 ~M optimal concentrations observed in 
this study to attenuate xpression of multiple growth 
factors simultaneously. Alternatively, growth factors 
can be added in combination or heterologous growth fac- 
tors can be added with antisense IGF-II to test for redun- 
dancy of action; or growth factors can be deleted by ho- 
mologous recombination (DeChiara et al. 1990), after 
which multiply homozygous mutants could be gener- 
ated to investigate the roles of growth factors that act 
through redundant circuits. 
That control of growth in early pre- and postimplan- 
tation mammalian embryos is regulated by genomic im- 
printing might be important from both developmental 
and evolutionary perspectives. Developmentally, expan- 
sion of different lineages of cells must be timed properly 
and maintained in proportion both intraembryonically 
and between the embryonic and maternal tissues. That 
imprinting is manifested from the two-cell stage, when 
zygotic transcription first occurs, suggests that the 
mechanisms for transcriptional regulation of these 
genes, at the level of either chromatin or DNA modifi- 
cation, are already stereotyped and in place when the 
genome is activated, much earlier than the mechanisms 
involved in X-chromosome inactivation (Lock et al. 
1987; for review, see Grant and Chapman 1988). Evolu- 
tionarily, it has been suggested that imprinting might 
occur because of conflicting parental interests in the 
growth rates of offspring in plants and viviparous organ- 
isms; male gene transmission is favored by fast embry- 
onic growth in competition with other males, whereas 
female gene transmission is favored by maximizing F1 
generation group size in competition with other females 
(Haig and Westoby 1989). In plants, the growth of the 
endosperm, the organ that acquires nutrients for the zy- 
gote, is under paternal control and is maternally im- 
printed {for eview, see Haig and Westoby 1989). In mam- 
mals, the growth of the placenta, the organ that acquires 
nutrients for the zygote or the embryo proper, would be 
predicted to be under paternal control. Positively acting 
elements in early embryonic growth circuits would be 
predicted to be paternally transcribed, and negatively 
acting elements would be predicted to be maternally 
transcribed. It is interesting to note that IGF-II ligand 
and receptor and IGF-I receptor are highly expressed in 
trophectoderm, the precursor to placenta, soon after im- 
plantation of rodent embryos, and that IGF-II functions 
in a paracrine manner in human placentation (Rotwein 
et al. 1987; Stylianopoulou et al. 1988; Ohlsson et al. 
1989a, b; Senior et al. 1990). 
The hypothesis of Haig and Graham (1991) predicts 
that imprinting of growth factors such as IGF-II, IGF-II 
receptor, and IGF-I receptor might regulate embryonic 
growth in mammals in utero. Our results showing im- 
printing of the IGF-I receptor and IGF-II ligand when 
inherited maternally are consistent with this hypothesis, 
but we cannot rule out the possibility that genomic im- 
printing of other growth factors and receptors may func- 
tion in maintaining balance in the proportion and timing 
of expansion of cell lineages in the embryo. Further stud- 
ies on the expression, function, and imprinting status of 
other elements in IGF growth circuitry (e.g., IGF-binding 
proteins}, and of other growth factor circuits, may delin- 
eate these hypotheses. The analysis of genes expressed in 
uniparental parthenogenetic and androgenetic embryos 
may serve as a rapid, general method for identifying e- 
nomically imprinted genes (Pedersen et al. 1992). 
It is notable that the IGF-II/mannose-6-phosphate re- 
ceptors in chicken and Xenopus do not bind IGF-II (Clair- 
mont and Czech 1989) and thus may function only in the 
transport of proteins targeted for lysosomes, whereas 
mammalian IGF-II/mannose-6-phosphate receptors bind 
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IGF-II as well as mannose-6-phosphate-rich proteins 
(MacDonald et al. 1988) through different extracellular 
domains. It has been hypothesized that the IGF-II recep- 
tor in mammals  suppresses growth by removing extra- 
cellular IGF-II (Haig and Graham 1991). Because of these 
evolutionary considerations, it will be interesting to 
evaluate the structure of the IGF-II receptor and its func- 
tion in early embryogenesis n greater detail. There is 
evidence that IGF-II can stimulate growth in cells only 
after stimulation by other growth factors (Nishimoto 
and Kojima 1989), and that this effect may depend on 
Ca 2 + influx, which depends on IGF-II binding to a Gi2- 
binding IGF-II/mannose-6-phosphate receptor (Nishim- 
oto and Kojima 1989; Okamoto et al. 1990a, b). However, 
the Ca 2 +-dependent mitogenic signal may also be medi- 
ated by IGF-II stimulation of the IGF-I receptor (Nishi- 
moto and Kojima 1989). Our data strongly suggest hat 
the IGF-II receptor is not the transducer of the mitogenic 
signal of endogenous IGF-II. The mitogenic signal of IGF- 
II might be transduced by the IGF-I receptor or insulin 
receptor. The insulin receptor (Sakano et al. 1991) and 
IGF-I receptor (Roth 1988) can bind IGF-II nearly as well 
as their cognate ligands. It is not clear from our data 
whether the mitogenic activity of IGF-II in embryos is 
transduced by the IGF-I or insulin receptors, but atten- 
uation of the expression of these receptors may distin- 
guish between these possibilities. 
Our data are the first to show directly that an endog- 
enous growth factor plays a role in cell proliferation dur- 
ing the earliest stages of mouse development. Our re- 
sults complement he analysis of long-term effects of 
IGF-II ligand on later embryonic and fetal growth in an- 
imals containing a mutant  IGF-II gene (DeChiara et al. 
1990). However, our understanding of the role of IGF-II 
in preimplantation mouse embryogenesis will require 
further studies. It is possible that growth rates during 
peri-implantation development are decisive in the estab- 
l ishment and proliferation of the extraembryonic lin- 
eages and, thereby, in the subsequent growth rate of the 
fetus. Still to be evaluated are synergism with other 
growth factors, signal transduction and gene induction 
by embryonic IGF-II, and location and function of the 
IGF-binding proteins in peri-implantation mouse em- 
bryos. 
Mater ia ls  and methods  
Materials 
Amplitaq DNA polymerase was purchased from Perk(n-Elmer 
Cetus. Restriction enzymes and T4 polynucleotide kinase were 
purchased from New England BioLabs and Bethesda Research 
Laboratories (BRL). Radioisotopes were obtained from New En- 
gland Nuclear. Moloney murine leukemia virus (MMLV) re- 
verse transcriptase and Superscript MMLV reverse transcriptase 
were obtained from BRL. Ant(sense, sense, and PCR oligonu- 
cleotides were obtained from the University of California t San 
Francisco (UCSF) Biomolecular Resource Center or synthesized 
in our laboratory on an Applied Biosystems PCR-Mate oligo- 
synthesizer. Biosynthetic insulin and IGF-II were gifts of Eli 
Lilly, and recombinant human IGF-II and IGF-I were purchased 
separately from Bachem. Polyclonal rabbit anti-rat IGF-II anti- 
body and rat IGF-II/multiplication stimulation activity (MSA) 
were gifts of P. Nissley (National Institutes of Health). 
[Leu27]IGF-II and recombinant IGF-I (Amgen) were the gifts of R. 
Rosenfeld (Stanford University). The IGF-I from Bachem was of 
lower specific activity than that from Amgen. 
Mouse eggs and embryos 
Standard techniques were used for obtaining eggs and zygotes 
(Hogan et al. 1986). Female CD-1 or CF-1 mice (6-10 weeks old, 
Charles River) were injected with 10 IU of pregnant mares' se- 
rum gonadotropin (Equitech), followed by an injection 44-48 hr 
later of 5 IU of human chorionic gonadotropin (hCG, Serono). 
After the second injection, females were housed overnight with 
C57BL/6J x SJL/J F 1 hybrid males {Jackson Laboratories). Em- 
bryos were obtained at the following stages: one-cell [12 hr post- 
co(turn (p.c.)], two-cell (36 hr p.c.), four-cell {48 hr p.c.), eight- 
cell (60 hr p.c.), and blastocyst (84-96 hr p.c.). Unfertilized eggs 
were flushed from the oviducts of superovulated females, and 
later embryos were dissected from the uteri of females (7.5 or 
8.5 d.g.). Embryos were flushed from the uteri or oviducts of 
mice with flushing medium-I (FM-I) (Spindle 1980) containing 3
mg/ml of bovine serum albumin. The embryos were then 
washed through 6 drops of FM-I. Mature oocytes/unfertilized 
eggs were flushed from oviducts 18 hr after hCG injection and 
then treated with hyaluronidase to remove adherent cumulus 
cells (Hogan et al. 1986). All eggs and embryos were sorted and 
freed of debris under a dissecting microscope. 
Parthenogenetic embryos 
Parthenogenetic activation of mouse oocytes was performed es- 
sentially as described by Barton et al. (1987), with minor mod- 
ifications (K.S. Sturm, M.L. Flannery, and R.A. Pedersen, un- 
publ.). Briefly, C57BL/6J x CBA/J F 1 female mice were induced 
to superovulate by injection of pregnant mares' serum gonado- 
tropin followed by hCG 48-50 hr later. Ovulated oocytes were 
activated 19-21 hr after hCG injection. Mature oocytes were 
activated in embryo culture medium (TE) (Spindle 1990) con- 
taining 6% ethanol (vol/vol) and 50 ~tM EDTA for 4.5 min, 
washed through FM-I, and transferred to TE containing 50 lzM 
EDTA and 0.5 ~g/ml of cytochalasin D for 5 hr to block extru- 
sion of the second polar body. The parthenogenetic embryos 
were then washed through FM-I, and intact embryos were trans- 
ferred in groups of 20 to individual drops of TE containing 50 fzM 
EDTA and cultured at 37°C. The efficiency of activation, deter- 
mined from two-cell parthenogenetic embryos at 24 hr, was 
65-85%. Control zygotic embryos were produced by mating F 1 
females with F~ males. Parthenogenetic outgrowths were cul- 
tured in outgrowth medium {Spindle 1990) for 3-7 days after 
hatching of blastocysts. 
Embryo culture 
For each analysis, 30-40 embryos were cultured from the two- 
cell stage in CZB medium (Chatot et al. 1989) or 20 embryos/ 
20-~1 drop in TE (Spindle et al. 1990) under paraffin oil (Aldrich) 
to the blastocyst stage. All experiments were performed at least 
twice. 
Biosynthetic labeling of embryos 
Two-cell embryos (400-600) were incubated for 48 hr in TE 
alone or in TE with 100 nM IGF-II, insulin (Eli Lilly), or IGF-I 
(Bachem). For the last 4 hr, embryos were incubated with or 
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without fresh growth factors and 1 mCi/ml of [3SS]methionine 
(3000 Ci/mmole} as described previously (Brenner et al. 1989). 
At the end of the labeling period, embryos were washed through 
8 drops of TE and duplicate samples from triplicate drops pre- 
cipitated onto glass filters by using 6% TCA (wt/vol), and dried 
and assayed by liquid scintillation spectrometry. In some exper- 
iments, the washed embryos were solubilized in loading buffer 
and applied directly and proteins were separated by 12% SDS-- 
polyacrylamide gel electrophoresis and analyzed by fluorogra- 
phy. 
RNA preparation 
A microadaptation (Rappolee t al. 1988a, 1989) of the guani- 
dine isothiocyanate (GuSCN)-CsC1 gradient ultracentrifuga- 
tion technique was used to prepare total RNA from 100--200 
embryos {Chirgwin et al. 1979). Embryos flushed from the gen- 
ital tract at specific stages or cultured to specific stages were 
washed though 6 drops of FM-I, solubilized in 100 ~1 of GuSCN 
containing 20 ~g of Escherichia coli rRNA (Boehringer Mann- 
helm), and layered over 100 ~1 of 5.7 M CsC1 and centrifuged for 
2 hr at 80,000 rpm in a TL-100A rotor in a Beckman TL-100 
benchtop ultracentrifuge. Yields of RNA were based on carrier 
amount and ranged from 35% to 80%. RNA used for positive 
controls was isolated from macrophages or retinoic acid-treated 
F9 cells, as described previously (Rappolee t al. 1988b; Brenner 
et al. 1989; Hahnel et al. 1990). The concentration of RNA was 
determined by measurement of absorbance at 260 nm. 
RT-PCR 
RT-PCR was performed essentially as described previously 
(Rappolee t al. 1988a,b, 1989). Briefly, RNA was reverse tran- 
scribed with MMLV reverse transcriptase or Superscript MMLV 
reverse transcriptase primed with 0.2 p~g of random hexanucle- 
otides (Pharmacia) or 0.5 ~g of 12- to 18-mer oligo(dT) (Collab- 
orative Research) with 100 units of enzyme in a 20-~1 mixture. 
In early studies on IGF-II expression, reaction mixtures were 
heat denatured and flash cooled; 50 units of additional buffered 
Superscript MMLV was added, and the RT mixture was reincu- 
bated. The proportion of the RT mixture that was equivalent to 
10 embryos was added to sequence-specific primed PCR reac- 
tion mixture in a buffer containing 10 mM Tris-HC1 (pH 8.3), 
600 t~M each dNTP, 5 ~M trimethyl ammonium chloride 
(Sigma), and 4.0 mM MgC12 in a 50-~1 reaction mixture (Rap- 
polee et al. 1988a). The mixture was overlaid with 100 ~1 of 
mineral oil and amplified for 60 cycles on a Perkin-Elmer Cetus 
Thermocycler programmable heating block. The PCR frag- 
ments were separated on a 4% agarose (3% GTG/I% Seakem, 
FMC Corp.) gel and visualized by ethidium bromide staining. 
Gels were photographed with a Polaroid MP-4, and negative 
images were reversed. Fragments were verified by size, restric- 
tion enzyme mapping, sequence analysis, and Southern blot 
analysis as described previously (Brenner et al. 1989; Telford et 
al. 1990). For restriction enzyme analysis, the fragments were 
precipitated with ammonium acetate directly from the PCR 
mixture, washed twice with 70% ethanol, and digested accord- 
ing to the restriction enzyme manufacturer's instructions. 
For quantification of mRNA, PCR was performed with end- 
labeled oligonucleotides: 5 ~l of the 3' and 5' primers at 50 
pmole/~l was mixed with 5 ~1 of T4 polynucleotide kinase 
{10,000 U/ml; New England BioLabs) and 250 txCi of [y-32p]ATP 
and incubated overnight at ambient emperature (Chelly et al. 
1988). Unincorporated radionucleotides were removed, and the 
labeled primers were used in 24 reactions. Fourfold dilutions 
were mixed and amplified as described for 40 cycles (Fig. 7a). 
Products were separated by 6% polyacrylamide g l electropho- 
resis and autoradiographed, the bands were excised, and radio- 
activity was determined by liquid scintillation spectrometry. 
Immunofluorescence and nuclear staining 
For immunocytochemistry, blastocysts were either fixed in so- 
lution without centrifugation or centrifuged onto poly-t-lysine- 
coated coverslips in a Shandon cytocentrifuge at900 rpm for 30 
min and fixed in 2% paraformaldehyde (pH 7.2). The blastocysts 
were stained with rabbit polyclonal anti-rat IGF-II antibody (di- 
luted at 1 : 200) with or without 0.5 ~g of rat IGF-II to absorb the 
anti-IGF-II antibody. The primary antibody was followed by bi- 
otinylated anti-rabbit IgG and then with streptavidin-Texas 
Red as described previously (Rappolee t al. 1988a). Embryos 
fixed and stained in solution were viewed in rectangular micro- 
capillary tubes (Vitro Dynamics). Rhodamine-phalloidin was 
used to visualize actin as a control protein. All photography was 
performed with a Zeiss Photomicroscope III and water immer- 
sion 25 x or 63 x phase Plan-Neofluor lenses, and Tri-X film was 
exposed and developed under similar lighting conditions. 
To determine the response of embryos, IGF-I (Amgen), IGF-II 
(Eli Lilly), and [Leu2Z]IGF-II were serially diluted in 100-~1 vol- 
umes and added at appropriate concentrations with 20 two-cell 
embryos in 20-~1 droplets under oil and cultured for 3 days; 
blastocysts were then fixed onto glass coverslips and stained. 
For staining of nuclei, embryos were fixed in solution by 3 : 1 
(vol/vol) ethanol/glacial cetic acid, dried onto coverslips, and 
incubated in 1 ~g/ml of Hoechst 33258 in water for 5 rain and 
destained overnight (Handyside and Hunter 1984). Nuclei were 
photographed asdescribed above. 
Antisense oligonucleotide experiments 
To determine the incorporation of oligonucleotides into em- 
bryos, the sense and antisense oligonucleotides were end-la- 
beled as described above for RT-PCR. Compacted eight-cell em- 
bryos were incubated with 30 p~M labeled oligonucleotides for 24 
hr in 20-~1 drops of TE. Embryos were then washed six times 
and incubated in TE medium without labeled oligonucleotides 
for 6 hr, washed through 6 more drops of unlabeled medium, 
fixed onto microscope slides, coated with photographic emul- 
sion, and exposed and developed. Control embryos were incu- 
bated with 30 ~M unlabeled oligonucleotides for 24 hr, washed 
through medium with labeled oligonucleotides for 1 min, and 
treated as described above. In some experiments, blastocysts 
were washed and incorporation of labeled oligonucleotides per 
20 embryos was determined by liquid scintillation spectrome- 
try. Incorporation per blastocyst (counts per minute) was calcu- 
lated by dividing total counts per minute by the number of 
blastocysts. The number of oligonucleotide molecules per blas- 
tocyst was then determined from the specific activity of the 
labeled oligonucleotides (Holt et al. 1988). 
For determination of the effects of oligonucleotides on 
growth, two-cell embryos were cultured in 30 ~M sense or an- 
tisense IGF-II oligonucleotides in 20-vd drops of TE for 72 hr 
with or without 10 nM recombinant IGF-II. The percentage of
embryos reaching the blastocyst stage was determined by phase 
microscopy at 24-hr intervals. The effects on endogenous IGF-II 
were studied by centrifuging the embryos onto coverslips after 
72 hr and then staining for immunofluorescence with anti-IGF- 
II antibodies as described above. For determination of effects on 
specific mRNAs from the cultured embryos, RNA was isolated 
and IGF-II and GAPDH transcripts were assayed by RT-PCR 
and quantified as described above. Effects on cell number were 
determined by fixing embryos onto coverslips and counting nu- 
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clei after Hoechst staining as described above. All experiments 
were performed at least twice. All values are expressed as mean 
+S.D. for three replicates. 
Oligonucleotides 
The designs of oligonucleotides u ed in this study showing se- 
quence position by amino acid residue or nucleotide are given 
below. 
Initiation codon oligonucleotides IGF-II (mouse; amino acid 
- 24) antisense, 5'-TGGGGATCCCAGTGGGGTAC-3'; IGF-II 
(mouse; amino acid -24) sense, 5'-GTACCCCACTGGGATC- 
CCCA-3'. 
PCR primers IGF-II (mouse; amino acid 3) 5' primer, 5'-GGC- 
CCCGGAGAGACTCTGTGC-3'; IGF-II (mouse; amino acid 
87) 3' primer, 5'-GCCCACGGGGTATCTGGGGAA-3'; IGF-I 
{rat; amino acid 1) 5' primer, 5'-GGACCAGAGACCCTT- 
TGCGGGG-3'; IGF-I (rat; amino acid 70) 3' primer, 5'-GGCT- 
GCTTTTGTAGGCTTCAGTGG-3'; insulin (mouse; nucle- 
otide 1144) 5' primer, 5'-ATGCGCTTCCTGCCCCTGCTG- 
GC-3'; insulin (mouse; nucleotide 1931) 3' primer, 5'-CTGG- 
TAGAGGGAGCAGATGCTGGT-3'; IGF-II receptor (rat; nu- 
cleotide 5048)5' primer, 5'-TGTACACTCTTCTTCTCCTG- 
GCA-3'; IGF-II receptor (rat; nucleotide 5233) 3' primer, 
5'-AGAGATGTTGATGTAGAAGACAGG-3'; IGF-I receptor 
(human; nucleotide 3769) 5' primer, 5'-ACTGACCTCATGCG- 
CATGTGCTGG-3'; IGF-I receptor (human; nucleotide 4113) 3' 
primer, 5'-CTCGTTCTTGCGGCCCCCGTTCAT-3'; insulin 
receptor (human; nucleotide 3934) 5' primer, 5'-ACTGACCT- 
CATGCGCATGTGCTGG-3'; insulin receptor (human; nucle- 
otide 4252) 3' primer, 5'-GCCCGTTTTTCTTGCCTCCGT- 
TCAT-3'; GAPDH (rat/human; nucleotide 838) 5' primer, 
5'-TGACATCAAGAAGGTGAAG-3'; GAPDH (rat/human; 
nucleotide 1087) 3' primer, 5'-TCCTTGGAGGCCATGTAG- 
GCC-3'. The sources for the sequences and sequence positions 
used are as follows: mouse IGF-II (Stempien et al. 1986); rat 
IGF-I (Bell et al. 1986); mouse insulin (Wentworth et al. 1986); 
rat IGF-II receptor (unpublished sequence from D.O. Morgan, 
UCSF); human IGF-I receptor and insulin receptor (Ebina et al. 
1985; Ullrich et al. 1985, 1986). Actin oligonucleotides have 
been published previously (Rappolee t al. 1988a). 
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